P112: ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF MITAPIVAT IN ADULTS WITH NON--TRANSFUSION-DEPENDENT OR TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
Kevin H.M. Kuo(University Health Network), Maria Domenica Cappellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Lauren Czapla(Agios Pharmaceuticals (United States)), Bo Tong(AbbVie (United States)), Hanny Al‐Samkari(Harvard University), Sarah Gheuens(Biogen (United States)), Alì Taher(American University of Beirut Medical Center), Christina X. Chamberlain(Agios Pharmaceuticals (United States)), Vip Viprakasit(Siriraj Hospital), Antonios Kattamis, K Uhlig(Tufts University), Seema Sheth(Cornell University), D. Mark Layton(Imperial College Healthcare NHS Trust), Megan T. Lynch(University of Maryland, Baltimore)
Cited by 6
Related Papers
Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study
|The Lancet|2011|1.3k
Thalassaemia
|The Lancet|2017|763
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
|Neuromuscular Disorders|2019|636
Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel
|Haematologica|2014|389
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320